P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

Bibliographic Details
Main Authors:	Sylvain Choquet, Andrew Clark, Cécile Renard, Ben Uttenthal, Sridhar Chaganti, Ralf Ulrich Trappe, Patrizia Comoli, Xinyuan Duan, Baodong Xing, Charley Wu, Laurence Gamelin, Jan-Henrik Terwey, Anke Friedetzky, Daan Dierickx
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972440.80732.55

Similar Items

P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES
by: S. Choquet, et al.
Published: (2022-06-01)

S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE)
by: S. Prockop, MD, et al.
Published: (2022-06-01)

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)
by: Mahadeo Kris Michael, et al.
Published: (2023-08-01)

الاضطرابات التكاثرية اللمفاوية التالية للاغتراس سلبية فيروس ابشتاين بار EBV –Negative PTLD))
by: فراس حسين
Published: (2019-05-01)

الاضطرابات التكاثرية اللمفاوية التالية للاغتراس سلبية فيروس ابشتاين بار EBV –Negative PTLD))
by: فراس حسين
Published: (2019-05-01)

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
by: V. Dharnidharka, et al.
Published: (2022-06-01)

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
by: J. Sanz-Caballer, et al.
Published: (2022-06-01)

EBV & lymphoma
by: Dolores Caballero, (Coordinating Author)
Published: (2019-06-01)

EBV and Lymphomagenesis
by: Daniel G. Sausen, et al.
Published: (2023-04-01)

The Role of NK Cells in EBV Infection and EBV-Associated NPC
by: Yi Tian Png, et al.
Published: (2021-02-01)

EBV-induced T-cell responses in EBV-specific and nonspecific cancers
by: Qiuting Zhang, et al.
Published: (2023-09-01)

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
by: Thomas Mika, et al.
Published: (2019-12-01)

The EBV Gastric Cancer Resource (EBV-GCR): A Suite of Tools for Investigating EBV-Associated Human Gastric Carcinogenesis
by: Mikhail Y. Salnikov, et al.
Published: (2023-03-01)

The role of EBV-encoded miRNA in EBV-associated gastric cancer
by: Ting Liu, et al.
Published: (2023-06-01)

Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
by: Octavia Ramayanti, et al.
Published: (2018-03-01)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
by: Eric Lau, et al.
Published: (2021-02-01)

Long-term remission in a child with refractory EBV+ hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV+ -related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy
by: El-Mallawany, N, et al.
Published: (2011)

Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy.
by: El-Mallawany, N, et al.
Published: (2011)

Antiviral Drugs for EBV
by: Joseph S. Pagano, et al.
Published: (2018-06-01)

Progress in EBV Vaccines
by: Dwain G. van Zyl, et al.
Published: (2019-02-01)

EBV IN HODGKIN LYMPHOMA
by: Stefan Hohaus, et al.
Published: (2009-11-01)

From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity
by: Darja Kanduc, et al.
Published: (2020-08-01)

Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study)
by: Andrea Alberti, et al.
Published: (2023-10-01)

Clinical, virological and immunological aspects of adoptive cell therapy against EBV-related diseases
by: Anna Merlo, et al.
Published: (2009-09-01)

Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells.
by: J Luis Espinoza, et al.
Published: (2012-01-01)

??????? ??? ????? ????? ???????- ???Epstein-Barr virus(EBV) ????? ?????? ????? ????? ?? ?????? ?? ???
by: ستار عبود فارس, et al.
Published: (2019-05-01)

??????? ??? ????? ????? ???????- ???Epstein-Barr virus(EBV) ????? ?????? ????? ????? ?? ?????? ?? ???
by: ستار عبود فارس, et al.
Published: (2019-05-01)

Syntropy in Children with EBV Infection
by: L.A. Khodak, et al.
Published: (2015-05-01)

Roles of EBV in Haemopoetic Malignancies
by: Takahara Miki, et al.
Published: (2005-12-01)

EBV AND HIV-RELATED LYMPHOMA
by: Andrea Antinori, et al.
Published: (2009-11-01)

EBV-Associated Lymphoproliferative Disorders
by: Young Hyeh Ko
Published: (2021-04-01)

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens
by: Marija Rozman, et al.
Published: (2022-07-01)

EBV dUTPase: A Novel Modulator of Inflammation and the Tumor Microenvironment in EBV-Associated Malignancies
by: Marshall V. Williams, et al.
Published: (2023-01-01)

Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells
by: Qinyan Yin, et al.
Published: (2017-06-01)

Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders
by: James P. Dugan, et al.
Published: (2019-03-01)

Silencing of PD-1 combined with EBV-specific killer T cells for the treatment of EBV-associated B lymphoma
by: Jiaping Wang, et al.
Published: (2024-02-01)

Updates on Epstein–Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV
by: Naveed Ahmed, et al.
Published: (2022-12-01)

Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region
by: Patricia Bott, et al.
Published: (2022-04-01)

Spontaneous EBV-Reactivation during B Cell Differentiation as a Model for Polymorphic EBV-Driven Lymphoproliferation
by: Matthew A. Care, et al.
Published: (2023-06-01)

The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis
by: Weixing Liu, et al.
Published: (2021-03-01)